Production of viral vectors for gene therapy applications

Current Opinion in Biotechnology

Volumn 11, Issue 2, 2000, Pages 205-208

  Wu, Naxin ^a   Ataai, Mohammad M ^a  

^a 208 Ctr Biotechnol/Bioengineering   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ADENOVIRUS; BIOREACTOR; CELL CULTURE; CELL METABOLISM; GENE THERAPY; HALF LIFE TIME; HERPES SIMPLEX VIRUS; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; REVIEW; VIROGENESIS; VIRUS INFECTION; VIRUS REPLICATION; VIRUS TITRATION;

ADENOVIRIDAE; ANIMALS; CELL CULTURE TECHNIQUES; DEPENDOVIRUS; GENE THERAPY; GENETIC VECTORS; HUMANS; RETROVIRIDAE; SIMPLEXVIRUS; VIRUSES;

ADENO-ASSOCIATED VIRUS; ADENOVIRIDAE; HERPES; SIMPLEXVIRUS; UNIDENTIFIED RETROVIRUS;

EID: 0034108590     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0958-1669(00)00080-X     Document Type: Review

References (48)

1. Amant C., Berthou L., Walsh K. Angiogenesis and gene therapy in man: dream or reality? Drugs. 59:1999;33-36.
2. Morgan R.A. Genetic strategies to inhibit HIV. Mol Med Today. 5:1999;454-458.
3. Nabel G.J. Development of optimized vectors for gene therapy. Proc Natl Acad Sci USA. 96:1999;324-326.
4. Kay M.A., Liu D., Hoogerbrugge P.M. Gene therapy. Proc Natl Acad Sci USA. 94:1997;12744-12746.
5. Mahato R.I., Smith L.C., Rolland A. Pharmaceutical perspectives of nonviral gene therapy. Adv Genet. 41:1999;95-156.
6. Douglas, J.J.: Process development of viral vector. The Second Annual US Biotechnology Symposium Nov 7-9, 1999 Washington, DC.
7. Naldini L., Blomer U., Gallay P., Ory D., Mulligan R., Gage F.H., Verma I.M., Trono D. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 272:1996;263-267.
8. Miyoshi H., Takahashi M., Gage F.H., Verma I.M. Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector. Proc Natl Acad Sci USA. 94:1997;10319-10323.
9. Kafri T., Blomer U., Peterson D.A., Gage F.H., Verma I.M. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat Genet. 17:1997;314-317.
10. Kafri T., van Praag H., Ouyang L., Gage F.H., Verma I.M. A packaging cell line for lentivirus vectors. J Virol. 73:1999;576-584.
11. Amalfitano A., Hauser M.A., Hu H., Serra D., Begy C.R., Chamberlain J.S. Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted. J Virol. 72:1998;926-933.
12. Morsy M.A., Gu M., Motzel S., Zhao J., Lin J., Su Q., Allen H., Franlin L., Parks R.J., Graham F.L.et al. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc Natl Acad Sci USA. 95:1998;7866-7871.
13. Hardy S., Kitamura M., Harris-Stansil T., Dai Y., Phipps M.L. Construction of adenovirus vectors through Cre-lox recombination. J Virol. 71:1997;1842-1849.
14. Chen H.H., Mack L.M., Kelly R., Ontell M., Kochanek S., Clemens P.R. Persistence in muscle of an adenoviral vector that lacks all viral genes. Proc Natl Acad Sci USA. 94:1997;1645-1650.
15. Schiedner G., Morral N., Parks R.J., Wu Y., Koopmans S.C., Langston C., Graham F.L., Beaudet A.L., Kochanek S. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet. 18:1998;180-183.
16. Xiao X., Li J., Samulski R.J. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol. 72:1998;2224-2232. By supplying the helper function from a plasmid, Xiao et al. first reported a helper-virus free system for production of adeno-associated virus vectors.
17. Grimm D., Kern A., Rittner K., Kleinschmidt J.A. Novel tools for production and purification of recombinant adenoassociated virus vectors. Hum Gene Ther. 9:1998;2745-2760. Using a monoclonal antibody which specifically binds the assembled AAV particles, an innovative affinity purification procedure is reported here. This approach greatly simplifies and improves the purification of AAV vectors.
18. Costantini L.C., Jacoby D.R., Wang S., Fraefel C., Breakefield X.O., Isacson O. Gene transfer to the nigrostriatal system by hybrid herpes simplex virus/adeno-associated virus amplicon vectors. Hum Gene Ther. 10:1999;2481-2494.
19. Conway J.E., Zolotukhin S., Muzyczka N., Hayward G.S., Byrne B.J. Recombinant adeno-associated virus type 2 replication and packaging is entirely supported by a herpes simplex virus type 1 amplicon expressing Rep and Cap. J Virol. 71:1997;8780-8789.
20. Recchia A., Parks R.J., Lamartina S., Toniatti C., Pieroni L., Palombo F., Ciliberto G., Graham F.L., Cortese R., La Monica N., Colloca S. Site-specific integration mediated by a hybrid adenovirus/adeno-associated virus vector. Proc Natl Acad Sci USA. 96:1999;2615-2620.
21. Liu X.L., Clark K.R., Johnson P.R. Production of recombinant adeno associated virus vectors using a packaging cell line and a hybrid recombinant adenovirus. Gene Ther. 6:1999;293-299. The hybrid virus produced offers advantage of both virures.
22. McMenamin M.M., Byrnes A.P., Pike F.G., Charlton H.M., Coffin R.S., Latchman D.S., Wood M.J. Potential and limitations of a gamma 34.5 mutant of herpes simplex 1 as a gene therapy vector in the CNS. Gene Ther. 5:1998;594-604.
23. Wu N., Watkins S.C., Schaffer P.A., DeLuca N.A. Prolonged gene expression and cell survival after infection by a herpes simplex virus mutant defective in the immediate-early genes encoding ICP4, ICP27, and ICP22. J Virol. 70:1996;6358-6369.
24. Krisky D.M., Wolfe D., Goins W.F., Marconi P.C., Ramakrishnan R., Mata M., Rouse R.J., Fink D.J., Glorioso J.C. Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons. Gene Ther. 5:1998;1593-1603.
25. Spaete R.R., Frenkel N. The herpes simplex virus amplicon: a new eucaryotic defective-virus cloning-amplifying vector. Cell. 30:1982;295-304.
26. Saeki Y., Ichikawa T., Saeki A., Chiocca E.A., Tobler K., Ackermann M., Breakefield X.O., Fraefel C. Herpes simplex virus type 1 DNA amplified as bacterial artificial chromosome in Escherichia coli: rescue of replication-competent virus progeny and packaging of amplicon vectors. Hum Gene Ther. 9:1998;2787-2794. It is a lengthy and complicated process to construct HSV vectors that have large viral genomes of 150 kb. Using BAC to amplify HSV genome and then to rescue HSV amplicon, this procedure takes advantage of the easy engineering of amplicon while eliminating the risk of helper virus contamination.
27. Simpson N.H., Milner A.E., Al-Rubeai M. Prevention of hybridoma cell death by bcl-2 during suboptimal culture conditions. Biotechnol Bioeng. 54:1997;1-16.
28. Mazur X., Eppenberger H.M., Bailey J.E., Fussenegger M. A novel autoregulated proliferation-controlled production process using recombinant CHO cells. Biotechnol Bioeng. 65:1999;144-150.
29. Manfredi J.J., Prives C. The transforming activity of simian virus 40 large tumor antigen. Biochim Biophys Acta. 1198:1994;65-83.
30. Henderson S., Huen D., Rowe M., Dawson C., Johnson G., Rickinson A. Epstein-Barr virus-coded BHRF1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death. Proc Natl Acad Sci USA. 90:1993;8479-8483.
31. Mastrangelo A.J., Zou S., Hardwick J.M., Betenbaugh M.J. Antiapoptosis chemicals prolong productive lifetimes of mammalian cells upon Sindbis virus vector infection. Biotechnol Bioeng. 65:1999;298-305.
32. Mercille S., Jolicoeur P., Gervais C., Paquette D., Mosser D.D., Massie B. Dose-dependent reduction of apoptosis in nutrient-limited cultures of NS/0 myeloma cells transfected with the E1B-19K adenoviral gene. Biotechnol Bioeng. 63:1999;516-528.
33. Wechuck J.C., Glorioso J.C., Ataai M.M. Effect of protease inhibitors on propagation and yield of viral vectors in Herpes-based viral vectors. Biotechnol Prog. 2000;. in press.
34. Kotani H., Newton P.B. III, Zhang S., Chiang Y.L., Otto E., Weaver L., Blease R.M., Anderson W.F., McGarrity G.J. Improved methods of retroviral vector transduction and production for gene therapy. Hum Gene Ther. 5:1994;19-28.
35. Morgan J.R., LeDoux J., Snow R.G., Tompkins R.G., Yarmush M.L. Retrovirus infection: effect of time and target cell number. Virology. 69:1995;6994-6999.
36. Lee S.G., Kim S., Robbins P.D., Kim B.G. Optimization of environmental factors for the production and handling of recombinant retrovirus. Appl Microbiol Biotechnol. 45:1996;477-483.
37. Kaptein L.C.M., Greijer A.E., Valerio D., van Beusechem V.W. Optimized conditions for the production of recombinant amphotropic retroviral vector preparations. Gene Ther. 4:1997;172-176.
38. Le Doux J.M., Davis H.E., Morgan J.R., Yarmush M.L. Kinetics of retrovirus production and decay. Biotechnol Bioeng. 63:1999;654-662.
39. Haldankar R., Kopchick J.J., Ridgway D. Stable production of a human growth hormone antagonist from CHO cells adapted to serum-free suspension culture. Biotechnol Prog. 15:1999;336-346.
40. Cote J., Garnier A., Massie B., Kamen A. Serum-free production of recombinant proteins and adenoviral vectors by 293SF-3F6 cells. Biotechnol Bioeng. 59:1998;567-575.
41. Siegwart P., Cote J., Male K., Luong J.H., Perrier M., Kamen A. Adaptive control at low glucose concentration of HEK-293 cell serum-free cultures. Biotechnol Prog. 15:1999;608-616.
42. Cote J., Bourget L., Garnier A., Kamen A. Study of adenovirus production in serum-free 293SF suspension culture by GFP-expression monitoring. Biotechnol Prog. 13:1997;709-714.
43. Gerin P.A., Gilligan M.G., Searle P.F., Al-Rubeai M. Improved titers of retroviral vectors from the human FLYRD18 packaging cell line in serum- and protein-free medium. Hum Gene Ther. 10:1999;1965-1974.
44. Gerin P.A., Searle P.F., Al-Rubeai M. Production of retroviral vectors for gene therapy with the human packaging cell line FLYRD18. Biotechnol Prog. 15:1999;941-948.
45. O'Keeffe R.S., Johnston M.D., Slater N.K. The affinity adsorptive recovery of an infectious herpes simplex virus vaccine. Biotechnol Bioeng. 62:1999;537-545. These authors discussed using chromatography for purification of large DNA virus HSV.
46. Wistuba A., Kern A., Weger S., Grimm D., Kleinschmidt J.A. Subcellular compartmentalization of adeno-associated virus type 2 assembly. J Virol. 71:1997;1341-1352.
47. Zolotukhin S., Byrne B., Mason E., Zolotukhin I., Potter M., Chesnut K., Summerford C., Samulski R., Muzyczka N. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 6:1999;973-985.
48. Clark K.R., Liu X., McGrath J.P., Johnson P.R. Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses. Hum Gene Ther. 10:1999;1031-1039.